Skip to main content

Table 1 Laboratory values and clinical symptoms

From: Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report

  Before treatment After four cycles of DLd 3 months after ASCT
Serum VEGF (pg/mL) 5000 826 212
Hematologic 1.81 g/dL M-spike in serum electrophoresis 0.50 g/dL M-spike in serum electrophoresis Negative M-spike in serum electrophoresis, detectable M-protein in serum immunofixation
PET–CT FDG-avid lesion
SUVmax = 6.91
FDG-avid lesion
SUVmax = 4.04
FDG-avid lesion
SUVmax = 2.22
ONLS 5 1 0
MCV of median nerve (m/second) 36.1 36.6 43.5
Ascites Grade 2 Grade 1 Absent
Edema Grade 1 Absent Absent
Papilledema Grade 1 Grade 1 Absent
DLCO (%) 53 68.4 94.0
ECOG PS 2 1 0
  1. DLd, daratumumab, lenalidomide, and dexamethasone; ASCT, autologous stem cell transplantation; VEGF, vascular endothelial growth factor; M-spike, monoclonal spike; M-protein, monoclonal protein; PET–CT, positron emission tomography-computed tomography; FDG, fluorodeoxyglucose; SUV, standardized uptake value; ONLS, Overall Neuropathy Limitations Scale; MCV, motor nerve conduction velocity; DLCO, diffusing capacity for carbon monoxide; ECOG PS, Eastern Cooperative Oncology Group performance status.